Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.

Abstract

To evaluate effectiveness and healthcare resource utilization (HCRU) of empagliflozin versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in Swedish clinical practice, as part of the EMPRISE EU study (EUPAS27606, NCT03817463). A non-interventional, cohort study using retrospectively collected data from Swedish national registries. Adults with type 2 diabetes newly initiated on empagliflozin or DPP-4i from May 2014 to December 2018 were matched 1:1 using propensity scores based on >180 covariates. Cardiovascular outcomes included hospitalization for heart failure (HHF), all-cause mortality (ACM), myocardial infarction (MI), stroke and cardiovascular mortality (CVM), as well as their composite outcomes. Renal outcomes included end-stage renal disease (ESRD), estimated glomerular filtration rate (eGFR) decline to <60 ml/min/1.73 m2 and progression to micro/macroalbuminuria. HCRU outcomes were also assessed. Comparisons were done using Cox proportional hazards and Poisson regression models. Overall, 15,785 matched-pairs were identified, with a mean follow-up of 6.4 and 9.7months for patients initiating empagliflozin versus DPP-4i, respectively. Empagliflozin was associated with significant reduction in rates of HHF (hazard ratio [HR]=0.67; 95% confidence interval: 0.49-0.91), ACM (HR=0.53; 0.41-0.68), HHF + ACM (HR=0.59; 0.48-0.73), MI + stroke + ACM (HR=0.68; 0.57-0.81), CVM (HR=0.46; 0.29-0.73), HHF + CVM (HR=0.61; 0.47-0.79) and MI + stroke + CVM (HR=0.79; 0.63-0.98) versus DPP-4i. Empagliflozin also reduced the rates of ESRD (HR=0.13; 0.03-0.57) and eGFR decline (HR=0.83; 0.70-0.99). Regarding HCRU, empagliflozin was associated with lower risk of first inpatient stay (HR=0.87; 0.81-0.93), and lower rate of inpatient and outpatient visits (rate ratio [RR]=0.85; 0.80-0.89 and RR=0.96; 0.94-0.98) than DPP-4i. Empagliflozin treatment compared to DPP-4i reduced cardiorenal events and overall mortality, which may explain lower HCRU among empagliflozin users in Sweden.